<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441375</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670A2418</org_study_id>
    <nct_id>NCT01441375</nct_id>
  </id_info>
  <brief_title>Sickle Cell Disease: A Retrospective Chart Review</brief_title>
  <official_title>Complications in Patients With Sickle Cell Disease and Utilization of Iron Chelation Therapy: A Retrospective Medical Records Review</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is a retrospective chart review of sickle cell patients and will include patients
      whom have received blood transfusions and those whom have not. Of the transfused patients, it
      will also include those whom have received chelation therapy and those whom have not.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sickle cell complications</measure>
    <time_frame>average of 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Utilization of health care delivery to treat sickle cell complications</measure>
    <time_frame>average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utilization of blood transfusions (patients with frequent transfusions only)</measure>
    <time_frame>average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of iron overload (patients with frequent transfusions only)</measure>
    <time_frame>average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utilization of Iron Chelation Therapies (ICTs) (patients receiving deferoxamine or deferasirox [Exjade®] only)</measure>
    <time_frame>average of 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">261</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <arm_group>
    <arm_group_label>Sickle cell patients non-transfused</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sickle cell patients transfused with no ICT</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sickle cell patients transfused with ICT</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Sickle cell anemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a diagnosis of Sickle Cell Disease (SCD) and a confirmed genotype

          2. Patients ≥ 16 years of age

          3. Patients with ≥ 6 months of follow-up data available from first SCD treatment at the
             center after they reach 16 years old

          4. At least one SF reading during a non-acute phase on or after the first SCD treatment
             at the center after they reach 16 years old

        Exclusion Criteria:

          1. Patients who participated in a clinical trial for an iron chelating medication or in a
             clinical trial for transfusions for SCD (1) within the six months before the index
             date or (2) during the patient observation period

          2. Patients with sickle cell trait

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2011</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle cell anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

